<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dissecting cellulitis of the scalp</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dissecting cellulitis of the scalp</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dissecting cellulitis of the scalp</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew F Alexis, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Hordinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H192597682"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dissecting cellulitis of the scalp (DCS), also known as perifolliculitis capitis abscedens et suffodiens or Hoffman disease, is a chronic inflammatory disorder of the scalp characterized by boggy, suppurative nodules that are often associated with patchy hair loss  (<a class="graphic graphic_picture graphicRef91508 graphicRef75929 graphicRef103149 graphicRef103150 graphicRef103151" href="/z/d/graphic/91508.html" rel="external">picture 1A-E</a>). Follicular occlusion may be a key pathogenic event in the development of DCS. DCS may occur in association with other follicular occlusive disorders, such as acne conglobata, hidradenitis suppurativa, and pilonidal cysts [<a href="#rid1">1</a>].</p><p>Data on treatment options for DCS are limited. Oral antibiotics and oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> are the most used treatments  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment'</a> below.)</p><p>The clinical features, diagnosis, and management of DCS will be reviewed here. An overview of the characteristics and diagnosis of hair loss is provided separately. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p>Other follicular occlusive disorders are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Acne conglobata'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/87056.html" rel="external">"Pilonidal disease"</a>.)</p><p></p><p class="headingAnchor" id="H503059288"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>DCS is a type of primary cicatricial (scarring) alopecia, a group of inflammatory disorders that target hair follicles and result in follicular destruction and permanent hair loss. A classification scheme proposed by the participants of a 2001 workshop on cicatricial alopecia sponsored by the North American Hair Research Society further classified DCS as a neutrophilic form of primary cicatricial alopecia based upon pathologic features [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Classification'</a> and <a class="local">'Histopathology'</a> below.)</p><p class="headingAnchor" id="H192597694"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of DCS is unknown, but DCS appears to be an uncommon disorder. Adult males account for the majority of affected patients, with a typical age of onset between 20 and 40 years. Occasionally, DCS occurs in adolescents and females [<a href="#rid3">3-7</a>]. In a multicenter retrospective study of patients seen at specialist hair clinics, DCS accounted for only 3 percent of the 840 cases of cicatricial alopecia [<a href="#rid8">8</a>]. Among the patients with DCS, 76 percent were male, and the median age was 37 years.</p><p>Although the largest published case series have arisen from Asia and Europe, DCS likely occurs globally [<a href="#rid5">5,7-14</a>]. Although clinical experience suggests that Black males are the most frequently affected population in the United States, epidemiologic data are insufficient to confirm this conclusion [<a href="#rid15">15-17</a>].</p><p>An association of DCS with smoking has been proposed but has not been confirmed. In a case-control study with 33 patients with DCS and 304 controls, current smoking was more common among patients with DCS than among the controls (odds ratio 6.47, 95% CI 2.77-15.13) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H192597700"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The etiology of DCS is unknown. A defect in follicular keratinization leading to obstruction of the follicle is suspected to contribute to the development of DCS. This theory is supported by the observation that DCS occurs in association with other disorders of follicular occlusion. (See <a class="local">'Associated disorders'</a> below.)</p><p>Proposed pathogenic events in DCS are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Sebaceous and keratinous material accumulates within dilated hair follicles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Release of this material into the dermis triggers an intense neutrophilic inflammatory reaction followed by abscess and sinus tract formation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary bacterial infection can occur, leading to exacerbation of the disease.</p><p></p><p class="headingAnchor" id="H192597706"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The major clinical features of DCS are suppurative nodules, interconnecting sinuses, hair loss, and a chronic course.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suppurative nodules and sinuses</strong> – DCS usually manifests as boggy, suppurative nodules on the vertex, parietal, and posterior scalp  (<a class="graphic graphic_picture graphicRef91508 graphicRef75929 graphicRef103149 graphicRef103150 graphicRef103151" href="/z/d/graphic/91508.html" rel="external">picture 1A-E</a>); however, other sections of the scalp can be affected. Drainage of pus or blood from involved skin is common. Because interconnecting sinuses are often present between nodules, the application of pressure to a nodule can result in drainage from a distant site. Patients often use head scarves, hats, or gauze dressings to hide these clinical manifestations. Pain or pruritus may be present [<a href="#rid9">9,10,19</a>].</p><p></p><p class="bulletIndent1">Exudate from nodules of DCS is usually sterile; however, secondary infection can occur. <em>Staphylococcus aureus</em> [<a href="#rid20">20</a>], <em>Pseudomonas aeruginosa</em> [<a href="#rid3">3</a>], and anaerobic bacteria [<a href="#rid21">21</a>] have been isolated from sites of DCS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair loss</strong> – Hair loss in DCS is usually patchy and most prominent on the skin overlying nodules. Although hair loss can be reversible in early stages of disease, scarring alopecia can develop in persistent cases [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease course</strong> – The clinical course of DCS is chronic. Patients frequently experience periodic flares of varying severity depending on the degree of inflammation. Hypertrophic or keloidal scarring may occur  (<a class="graphic graphic_picture graphicRef81039" href="/z/d/graphic/81039.html" rel="external">picture 2</a>).</p><p></p><p class="headingAnchor" id="H503059023"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>Other follicular occlusion disorders and other conditions may occur in association with DCS.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follicular occlusion tetrad</strong> – DCS is considered a component of the follicular occlusion tetrad, a group of four disorders (hidradenitis suppurativa, acne conglobata, DCS, and pilonidal sinus) thought to have follicular occlusion as a key pathogenic event. Patients with DCS may exhibit other disorders in the follicular occlusion tetrad [<a href="#rid5">5,7,14,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Acne conglobata'</a> and  <a class="medical medical_review" href="/z/d/html/87056.html" rel="external">"Pilonidal disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other disorders</strong> – Additional disorders, such as marginal keratitis [<a href="#rid24">24</a>], arthritis, spondyloarthropathy [<a href="#rid25">25</a>], keratitis-ichthyosis-deafness (KID) syndrome [<a href="#rid26">26</a>], and sternoclavicular hyperostosis, also have occurred in patients with DCS [<a href="#rid1">1,27-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'KID syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/99510.html" rel="external">"SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H192597718"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>Histopathologic features of DCS vary according to the stage of the disease and severity. Characteristic histologic findings of DCS are dense, predominantly neutrophilic, mixed-cell perifollicular infiltrates in the dermis. There may be abscesses in the dermis or subcutaneous tissue [<a href="#rid1">1</a>].</p><p>Follicular dilatation may be evident in early disease [<a href="#rid15">15,22</a>]. Granulomatous inflammation, scarring, and fibrosis are common in advanced or late-stage disease [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H192597724"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of DCS can usually be made based upon the patient history and physical examination, although a culture should be performed to rule out secondary infection. In addition, a biopsy may be necessary to confirm the diagnosis and rule out other forms of cicatricial alopecia if overlapping features are present. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Cicatricial alopecia'</a>.)</p><p>In general, the diagnosis should be suspected in patients with a chronic, relapsing eruption characterized by multiple boggy, suppurative nodules on the scalp. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H503059433"><span class="h2">History and physical examination</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient history</strong> – The patient history should include an assessment of the duration of hair loss and associated symptoms. Patients with DCS typically mention chronic and recurrent scalp nodules associated with purulent or bloody drainage.</p><p></p><p class="bulletIndent1">Given the association of DCS with other disorders in the follicular occlusion tetrad, patients should also be asked about a history of signs or symptoms of hidradenitis suppurativa, acne conglobata, or pilonidal cysts. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/87056.html" rel="external">"Pilonidal disease"</a> and  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Acne conglobata'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The physical examination of the hair and scalp should include an assessment of the distribution and extent of involvement. Boggy nodules, typically 1 to 3 cm in diameter, involving the posterior and vertex scalp are typical of DCS. Palpation of the scalp aids in the detection of the classic boggy texture. Drainage of pus or blood and patches of alopecia overlying nodules are common findings.</p><p></p><p class="bulletIndent1">The physical examination of the scalp may also help to assess for the likelihood of hair regrowth. A loss of follicular orifices suggests permanent scarring alopecia. General principles for the clinical evaluation of patients with hair loss are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1">Performance of a full skin examination is helpful for identifying patients with concomitant hidradenitis suppurativa, acne conglobata, or pilonidal cysts. (See  <a class="medical medical_review" href="/z/d/html/5575.html" rel="external">"Hidradenitis suppurativa: Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/87056.html" rel="external">"Pilonidal disease"</a> and  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Acne conglobata'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermoscopy</strong> – Dermoscopy may be a useful adjunctive procedure in the clinical assessment of patients with DCS. (See  <a class="medical medical_review" href="/z/d/html/110157.html" rel="external">"Overview of dermoscopy of the hair and scalp"</a>.)</p><p></p><p class="bulletIndent1">Common findings are as follows [<a href="#rid31">31</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early disease</strong> – Empty follicular openings, yellow dots, and black dots</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advanced disease</strong> – Yellow, structureless areas and three-dimensional yellow dots imposed over dystrophic hair shafts</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>End-stage disease</strong> – Confluent, ivory-white areas without follicular openings</p><p></p><p class="headingAnchor" id="H1400626888"><span class="h2">Culture</span><span class="headingEndMark"> — </span>A bacterial culture should be performed to rule out bacterial infection. However, in most cases, exudate associated with DCS is sterile. (See <a class="local">'Active infection'</a> below.)</p><p class="headingAnchor" id="H586652392"><span class="h2">Scalp biopsy</span><span class="headingEndMark"> — </span>If the diagnosis of DCS is uncertain, a scalp biopsy should be performed to confirm the diagnosis and differentiate DCS from other cicatricial alopecias. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Scalp biopsies'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – A 4 mm punch biopsy is usually adequate. The preferred site for a biopsy is within a boggy, suppurative, or tender nodule; the goal is to sample a clinically active (ie, inflamed) lesion.</p><p></p><p class="bulletIndent1">Some dermatopathologists prefer to receive two scalp biopsy specimens to allow for examination of the tissue in both vertical and horizontal sections. However, a single biopsy can be sufficient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Classically, histologic examination of DCS reveals a perifollicular, neutrophil-predominant, mixed-cell inflammatory infiltrate. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="headingAnchor" id="H192597730"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of DCS includes other inflammatory or nodular disorders that affect the scalp.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Folliculitis decalvans</strong> – Folliculitis decalvans is an uncommon type of cicatricial alopecia that presents with multiple pustules and areas of scarring of the scalp. On examination, yellowish crusts or collarettes of scale at sites of ruptured pustules and tufted folliculitis (multiple hairs emerging from a single inflamed follicular orifice) are common findings  (<a class="graphic graphic_picture graphicRef91503 graphicRef87488" href="/z/d/graphic/91503.html" rel="external">picture 3A-B</a>). The deep-seated nodules characteristic of DCS are not a typical feature of folliculitis decalvans. (See  <a class="medical medical_review" href="/z/d/html/15685.html" rel="external">"Folliculitis decalvans"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acne keloidalis</strong> – Acne keloidalis is a form of cicatricial alopecia that most commonly presents with multiple fibrotic or keloid-like follicular papules on the posterior scalp  (<a class="graphic graphic_picture graphicRef87490 graphicRef97616" href="/z/d/graphic/87490.html" rel="external">picture 4A-B</a>). Patients with advanced disease may develop keloid-like plaques or nodules. Although scarring and keloids may occur as a consequence of DCS, fibrotic keloid-like papules or plaques are not the primary clinical feature in DCS. (See  <a class="medical medical_review" href="/z/d/html/15684.html" rel="external">"Acne keloidalis nuchae: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial folliculitis</strong> – Bacterial folliculitis is characterized by inflamed follicular papules or pustules  (<a class="graphic graphic_picture graphicRef97630" href="/z/d/graphic/97630.html" rel="external">picture 5</a>). Unlike DCS, large, boggy nodules or abscesses are not typical features of folliculitis. (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Bacterial folliculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pilar cysts</strong> – Pilar cysts present as solitary or multiple firm, slow-growing subcutaneous nodules on the scalp  (<a class="graphic graphic_picture graphicRef68396" href="/z/d/graphic/68396.html" rel="external">picture 6</a>). Occasionally, a pilar cyst may become inflamed or infected. The presence of multiple nodules that are boggy or suppurative helps to distinguish DCS from pilar cysts. (See  <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Pilar (trichilemmal) cysts'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kerion</strong> – Kerion is a severe manifestation of tinea capitis that results from an intense immune response to the infection. Patients develop an inflammatory plaque with pustules, crusting, or drainage  (<a class="graphic graphic_picture graphicRef86627" href="/z/d/graphic/86627.html" rel="external">picture 7</a>). Unlike DCS, kerion is most common in children. However, kerion mimicking DCS has been reported in adults and children [<a href="#rid32">32-34</a>]. (See  <a class="medical medical_review" href="/z/d/html/99983.html" rel="external">"Tinea capitis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H192597737"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of DCS is warranted given the chronic and progressive nature of the disease and the high likelihood for scarring and permanent alopecia. Our approach to the treatment of DCS is reviewed here. Other approaches may be reasonable.</p><p class="headingAnchor" id="H2663584283"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The key treatment strategies for DCS are to reduce inflammation, reduce follicular occlusion, and prevent and treat secondary infection. Systemic antibiotics, oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, biologic tumor necrosis factor (TNF)-alpha inhibitors, and surgical excision are the mainstays of treatment. However, treatment efficacy data are limited, precluding conclusions on the relative efficacy of these treatments.</p><p>Occasionally, patients present with very painful or fluctuant nodules for which an immediate intervention is necessary for symptom relief. Adjunctive therapies, such as intralesional corticosteroid injection and incision and drainage, appear useful in this setting. (See <a class="local">'Painful or very fluctuant lesions'</a> below.)</p><p>In our experience, incorporation of an adjunctive topical antimicrobial agent has also seemed to help reduce risk for secondary infection. (See <a class="local">'Adjunctive topical antimicrobial agents'</a> below.)</p><p class="headingAnchor" id="H3975846586"><span class="h2">Pretreatment assessment</span><span class="headingEndMark"> — </span>The pretreatment assessment should include an evaluation for secondary infection.</p><p class="headingAnchor" id="H1277299331"><span class="h3">Active infection</span><span class="headingEndMark"> — </span>Because of the possibility of secondary infection in DCS, a bacterial culture should be performed prior to treatment. If the culture identifies pathogenic bacteria, an appropriate antibiotic should be selected to treat the infection. The patient can then transition to treatment directed at the underlying disease. (See <a class="local">'Preferred initial therapy'</a> below.)</p><p class="headingAnchor" id="H1080185430"><span class="h2">Preferred initial therapy</span></p><p class="headingAnchor" id="H192597750"><span class="h3">Oral tetracyclines</span><span class="headingEndMark"> — </span>Oral antibiotic therapy with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is our preferred initial treatment for DCS. The anti-inflammatory and antibacterial effects of tetracyclines may contribute to benefit. In addition, tetracyclines are generally well tolerated.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – We typically begin treatment for adults with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (at a dose of 100 mg twice daily) for a period of three months. Lower daily doses of doxycycline have also been utilized [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with a satisfactory response to </strong><strong>doxycycline</strong> – If there is marked improvement after three months, we continue <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> for at least three additional months. Doxycycline may be continued at the same dose or reduced to a subantimicrobial dose (eg, 20 mg twice daily or 40 mg of immediate release/delayed release doxycycline once daily), with subantimicrobial dosing usually reserved for patients with milder disease presentations and complete resolution of disease activity. Treatment courses longer than six months may be necessary to reach optimal control for some patients who are responding to doxycycline. We stop doxycycline after there has been at least a three-month period of disease inactivity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with an unsatisfactory response to </strong><strong>doxycycline</strong> – If there is an unsatisfactory response after three months, we stop <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and either start <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (at a dose of 100 mg twice daily) or proceed to oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. In our experience, some patients who have inadequate responses to doxycycline exhibit greater improvement with minocycline. For patients with severe disease, we often proceed directly to oral isotretinoin. (See <a class="local">'Oral isotretinoin'</a> below.)</p><p></p><p class="bulletIndent2">As with patients responding to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, patients who achieve satisfactory responses after three months of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> therapy continue minocycline for an additional three months at the same dose or a reduced dose (eg, 50 mg twice daily). Minocycline can be stopped after a three-month period of disease inactivity. If there is no response to minocycline, we proceed to therapies for tetracycline-refractory disease. (See <a class="local">'Tetracycline-refractory disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who respond to tetracyclines but relapse</strong> – In our experience, patients who experience marked improvement with tetracyclines but relapse after cessation may benefit from a repeat course of antibiotic therapy or a transition to another therapy.</p><p></p><p class="bulletIndent2">When relapses are delayed and occur infrequently (eg, one or fewer relapses per year), we often prescribe a three-month course of the previously effective antibiotic (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily). For patients who respond to doxycycline, we often continue a subantimicrobial dose of doxycycline (at a dose of 20 mg of doxycycline twice daily or 40 mg [with 30 mg immediate release and 10 mg delayed release] of doxycycline once daily) as long-term maintenance therapy.</p><p></p><p class="bulletIndent2">For patients with rapid or more frequent relapses, we often proceed to oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. (See <a class="local">'Tetracycline-refractory disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Despite the frequent use of oral antibiotics for DCS, randomized trials evaluating antibiotic therapy are lacking. Partial responses to antibiotics may be common. In a retrospective study that included 10 patients with DCS treated with systemic antibiotics (six patients given <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [at a dose of 200 mg per day for three months] and four patients given <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> [both 300 mg twice daily for three months]), a complete response occurred in one patient, with the remaining nine patients having partial improvement [<a href="#rid12">12</a>]. In another retrospective study of 21 patients with DCS, four of five patients treated with doxycycline (mean daily dose of 100 mg per day) had "a great reduction in disease activity" [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1">Recurrence after cessation of antibiotic therapy may be common; in the study of 10 patients mentioned above, 9 had recurrence of disease activity [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential adverse reactions to tetracyclines include gastrointestinal symptoms (nausea, abdominal pain or discomfort); photosensitivity (particularly <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>); and, infrequently, pseudotumor cerebri. In addition, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> may cause dose-dependent vestibular effects, bluish skin dyspigmentation (usually following several months of therapy), lupus-like drug reactions, or drug reaction with eosinophilia and systemic symptoms (DRESS). (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="headingAnchor" id="H674145030"><span class="h2">Tetracycline-refractory disease</span><span class="headingEndMark"> — </span>The main treatments utilized for DCS that cannot be adequately controlled with tetracyclines include oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> combination therapy, biologic TNF inhibitors, and surgical excision. Efficacy data for these interventions are limited.</p><p class="headingAnchor" id="H4139592818"><span class="h3">Approach to treatment</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is our treatment of choice for DCS that does not respond well to oral tetracyclines  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>). Although some authors suggest isotretinoin as the preferred initial therapy for moderate to severe DCS [<a href="#rid35">35</a>], we generally try <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> prior to proceeding to isotretinoin because of doxycycline's relatively favorable adverse effect profile. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Adverse effects'</a>.)</p><p>Our approach to patients who cannot receive oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> or who experience inadequate or transient responses to oral isotretinoin is as follows  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who cannot receive or prefer to avoid oral </strong><strong>isotretinoin</strong> – Either treatment with a biologic TNF inhibitor or combination treatment with oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is our preferred next step for patients with disease that responds poorly to tetracyclines but who cannot receive or prefer to avoid oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. (See <a class="local">'Biologic TNF inhibitors'</a> below and <a class="local">'Clindamycin and rifampin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with disease that responds poorly to oral </strong><strong>isotretinoin</strong> – Treatment with a biologic TNF inhibitor is our preferred next therapy after failure of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, but long-term continuation of therapy may be necessary to maintain improvement. Surgical intervention is an alternative for patients who prefer a potentially curative procedural intervention and who are comfortable with the expected outcome of extensive scarring. (See <a class="local">'Biologic TNF inhibitors'</a> below and <a class="local">'Surgical excision'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who experience disease relapse after oral </strong><strong>isotretinoin</strong> – Mild relapses (eg, few relatively small, boggy nodules) can often be managed with a course of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and intralesional corticosteroid injections. (See <a class="local">'Oral tetracyclines'</a> above and <a class="local">'Painful or very fluctuant lesions'</a> below.)</p><p></p><p class="bulletIndent1">For moderate to severe relapses after oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, we tend to proceed to a biologic TNF-alpha inhibitor. Alternatively, our experience suggests that a repeat course of oral isotretinoin followed by long-term, low-dose isotretinoin (eg, 20 mg per day, increased to 1 mg/kg per day during flares) may also be beneficial. (See <a class="local">'Biologic TNF inhibitors'</a> below.)</p><p></p><p class="headingAnchor" id="H192597756"><span class="h3">Oral isotretinoin</span><span class="headingEndMark"> — </span>The mechanism of benefit for oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> in DCS is unclear but may relate to anti-inflammatory effects or inhibition of follicular occlusion. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Adverse effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Adults are usually treated with 0.5 to 1 mg/kg of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> per day. Our typical initial regimen consists of 1 mg/kg per day of isotretinoin. We assess the response after three months  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with a satisfactory response</strong> – Remission often occurs within three months in patients who respond to oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid10">10</a>]. Our clinical experience suggests that treatment should be continued for at least four months after resolution or marked reduction of clinically active lesions. We usually stop isotretinoin once this has been achieved.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with an unsatisfactory response</strong> – If there is no evidence of response after three months, we stop oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>.</p><p></p><p class="bulletIndent2">If there is a partial response after three months, we continue <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for an additional three months prior to reassessing efficacy. In our experience, the addition of adjunctive, once-monthly intralesional corticosteroid injections can be helpful in this setting. (See <a class="local">'Painful or very fluctuant lesions'</a> below.)</p><p></p><p class="bulletIndent2">If the response remains inadequate after six months, we stop <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>.</p><p></p><p class="bulletIndent2">Relapse several weeks to months after discontinuation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> may be common; however, in some patients, the severity of disease may be lower than prior to treatment. The severity of relapse influences our selection of subsequent treatment. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Support for use of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for DCS comes from retrospective studies and case series [<a href="#rid9">9-11,35-41</a>]. Data from several retrospective studies suggest partial or complete improvement rates of 75 to 100 percent of patients [<a href="#rid42">42</a>]. Examples of some of the largest retrospective studies include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective study of 51 patients with DCS, 33 of 35 patients treated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (at a dose of 0.5 to 0.8 mg/kg per day) experienced complete remission after three months [<a href="#rid10">10</a>]. However, relapses were common after treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective multicenter study involving 72 patients with DCS treated with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> at an average dose of 0.25 to 0.5 mg/kg until a cumulative dose of 120 to 150 mg/kg demonstrated reduced inflammatory signs in 90 percent of patients [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective study that included 16 patients treated with oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (at a dose of 20 to 40 mg per day based upon a dose equivalent to 0.3 to 0.7 mg/kg), responses were complete in six patients, partial in six patients, and absent in four patients [<a href="#rid7">7</a>]. The median time to initial response was 2 weeks (range 0.7 to 8 weeks), and the average cumulative dose of isotretinoin was 5731 mg (range 280 to 19,920 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential adverse effects of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> include dry skin and mucous membranes, hypertriglyceridemia, elevation of liver transaminases, vision changes, and teratogenicity. The drug is contraindicated in pregnancy. Adverse effects are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">In the United States, participation in a Risk Evaluation and Mitigation Strategy program (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipledgeprogram.com%2F&amp;token=11npaxc5%2BtwYQNEbNxIvNS6jn5isbc5PagiLZmaLXtU%2FC3Cjk8xMGmD5H6e3WFbI&amp;TOPIC_ID=15682" target="_blank">www.ipledgeprogram.com</a>) is required for <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> prescriptions.</p><p></p><p class="headingAnchor" id="H766276459"><span class="h3">Clindamycin and rifampin</span><span class="headingEndMark"> — </span>Combination treatment with oral <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and oral <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> may be beneficial for patients who have insufficient responses to tetracyclines but who prefer to avoid or cannot tolerate oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>). (See <a class="local">'Approach to treatment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Our typical regimen for adults is <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (at a dose of 300 mg twice daily) and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (at a dose of 300 mg twice daily) for three months. If the response is insufficient after three months, we cease treatment.</p><p></p><p class="bulletIndent1">Patients with a satisfactory response continue treatment for an additional three months. If marked improvement is maintained, we then stop the antibiotics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Efficacy data are limited. In a retrospective study that included 10 patients with DCS treated with systemic antibiotics (four patients given <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> [both 300 mg twice daily for three months] and six patients given <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [at a dose of 200 mg per day for three months]), a complete response occurred in one patient, with the remaining nine patients having partial improvement [<a href="#rid12">12</a>]. Isolated case reports also suggest benefit of clindamycin and rifampin [<a href="#rid1">1,9</a>]. Recurrence of disease activity after treatment may be common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Pseudomembranous colitis is a potential adverse effect of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>. <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> is associated with multiple drug interactions and may cause orange or red staining of body secretions, gastrointestinal distress, hepatitis, hematologic abnormalities, influenza-like syndromes, and other conditions. Adverse effects of these antibiotics are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/485.html" rel="external">"Clindamycin: An overview", section on 'Toxicity'</a> and  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H3669880889"><span class="h3">Biologic TNF inhibitors</span><span class="headingEndMark"> — </span>The biologic tumor necrosis factor (TNF) inhibitors <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> may be beneficial for DCS that cannot be adequately treated with antibiotics or oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>). (See <a class="local">'Approach to treatment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – We typically treat with <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>. The subcutaneous route of adalimumab is an advantage over the intravenous route of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>. Although a subcutaneously administered formulation of infliximab is available in some countries, published reports of infliximab benefit in DCS have assessed the intravenous formulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adalimumab</strong> – Our typical regimen for adults mirrors the dosing for hidradenitis suppurativa (ie, an initial 160 mg dose given subcutaneously, then 80 mg every other week starting at day 15) [<a href="#rid12">12,44</a>].</p><p></p><p class="bulletIndent2">However, other regimens have been utilized (eg, an initial 80 mg dose given subcutaneously, followed by 40 mg at week 1, then 40 mg every other week) [<a href="#rid45">45-47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infliximab</strong> – Dosing regimens used for <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> also vary. Some authors have utilized dosing similar to psoriasis dosing (at a dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks) [<a href="#rid45">45,48</a>], and others have used different regimens [<a href="#rid1">1,12,49</a>]. Higher doses (up to 10 mg/kg) may be necessary in severe, refractory cases.</p><p></p><p class="bulletIndent1">Signs of improvement with TNF inhibitors are often evident within the first one to three months of treatment [<a href="#rid12">12,44-47,50</a>].</p><p></p><p class="bulletIndent1">Best practice for the duration of biologic therapy is unclear. Because biologic treatment is not considered curative, we generally plan to continue treatment in patients who respond to biologic therapy. We reserve trials of treatment cessation to patients who have experienced long periods of complete remission (eg, &gt;1 year).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Case reports and small case series document improvement of refractory DCS with <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid12">12,44-47,50</a>] and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid45">45,49,51</a>]. In one retrospective study of eight patients treated with infliximab and one patient treated with adalimumab (alone or in conjunction with other systemic therapies), treatment was associated with reduced inflammatory nodules, reduced purulent drainage, and improvement in patient quality of life [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential adverse effects of biologic TNF-alpha inhibitors include injection site reactions, infusion reactions, neutropenia, serious infections, and other adverse effects. Adverse effects of these drugs are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p class="headingAnchor" id="H928771853"><span class="h3">Surgical excision</span><span class="headingEndMark"> — </span>Surgical therapy for DCS involves the excision of skin in affected areas of the scalp. Surgical excision is generally performed by a dermatologic surgeon or plastic surgeon experienced in the treatment of this condition. The expected outcome of scarring must be considered carefully when proceeding with surgical excision.</p><p>Multiple cases of sustained remission following surgical excision of affected areas of the scalp (with staged excisions and/or skin grafts) have been reported [<a href="#rid35">35,52</a>]. Short-term use of TNF-alpha inhibitor therapy to calm inflammation prior to surgical excision has been reported in a patient with severe DCS [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H414560133"><span class="h2">Painful or very fluctuant lesions</span><span class="headingEndMark"> — </span>Acute relief from the discomfort associated with an inflamed or suppurative nodule is sometimes necessary. Intralesional corticosteroid injections and incision and drainage are used to provide rapid, temporary symptom relief. These interventions do not alter the course of the disease and should not be used as primary treatment.</p><p>Selection between intralesional corticosteroid injection and incision and drainage is based upon the clinical presentation. Intralesional corticosteroid injection is our preferred intervention for painful, inflamed, nonfluctuant or minimally fluctuant nodules. We use incision and drainage for fluctuant lesions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intralesional corticosteroid</strong> – Intralesional injection is best performed by clinicians experienced with this procedure. To minimize risk for corticosteroid-induced skin atrophy, the concentration and total volume of injection should be commensurate with the degree of inflammation or fibrosis, as well as the size of the individual lesion. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection"</a>.)</p><p></p><p class="bulletIndent1">The typical dose range is 5 to 10 mg/mL of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide, depending on the severity of inflammation. Higher concentrations (eg, 10 to 40 mg/mL) may be useful for the treatment of associated hypertrophic scarring. (See  <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">"Keloids and hypertrophic scars", section on 'Treatment of hypertrophic scars'</a>.)</p><p></p><p class="bulletIndent1">A 30-gauge needle can be used for injection. We usually do not inject more than 40 mg of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide per treatment session to minimize risk for systemic adverse effects. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incision and drainage</strong> – Techniques for incision and drainage are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6336.html" rel="external">"Techniques for skin abscess drainage"</a>.)</p><p></p><p class="headingAnchor" id="H2502532447"><span class="h2">Adjunctive topical antimicrobial agents</span><span class="headingEndMark"> — </span>Topical antibiotics and topical antimicrobial agents are not considered effective primary treatments for DCS. In one retrospective study, 8 of 11 patients treated with topical antibiotics (drugs not specified) had no response to treatment, and the remaining three patients had partial responses and recurrences of disease activity [<a href="#rid12">12</a>].</p><p>However, our clinical experience suggests that regular use of topical antimicrobial cleansers (eg, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>, <a class="drug drug_general" data-topicid="9801" href="/z/d/drug information/9801.html" rel="external">povidone iodine</a>) as an adjunct to oral therapies for DCS may help to reduce risk for secondary infection. We typically instruct our patients to use an antimicrobial cleanser to wash the entire scalp during showering or bathing on a daily basis.</p><p class="headingAnchor" id="H1783528508"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Other treatments associated with improvement in DCS in small numbers of patients include oral <a class="drug drug_general" data-topicid="10328" href="/z/d/drug information/10328.html" rel="external">zinc sulfate</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, intracavitary foam sclerotherapy, radiation therapy, and application of a pressure dressing. Additional study is necessary to confirm efficacy of these interventions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotics</strong> – In a retrospective study that included four patients treated with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> (at a dose of 50 or 100 mg per day) for DCS, two had a complete response, and two had a partial response [<a href="#rid12">12</a>]. The mean treatment duration was nine months. In a case report, combination treatment with dapsone (at a dose of 100 mg per day) and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (at a dose of 80 mg per day) was associated with clinical improvement within four weeks after failure of isotretinoin monotherapy [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent2">Benefit of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid9">9</a>] and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid54">54-56</a>] has also been documented in case reports.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other biologic drugs</strong> – The interleukin (IL) 23 inhibitors <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a> [<a href="#rid57">57</a>] and <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a> [<a href="#rid58">58,59</a>] and the IL-17 inhibitor <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> [<a href="#rid60">60</a>] have appeared beneficial for individual patients with refractory DCS [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral </strong><strong>zinc sulfate</strong> – Improvement with oral <a class="drug drug_general" data-topicid="10328" href="/z/d/drug information/10328.html" rel="external">zinc sulfate</a> is described in case reports. In one case report, a patient treated with oral zinc sulfate for six months had disappearance of nodules and hair regrowth within the first three weeks, complete healing after three months of therapy, and sustained remission for at least five years [<a href="#rid61">61</a>]. In another report, an adolescent with DCS and acne conglobata had flattening of nodules within 4 weeks and hair regrowth after 12 weeks but required continued treatment with a lower dose of oral zinc sulfate to maintain improvement [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral corticosteroids</strong> – Oral corticosteroids are not used as a primary treatment for DCS but are sometimes prescribed as adjunctive therapy for highly inflammatory presentations of DCS [<a href="#rid7">7,35</a>]. We do not use oral corticosteroids for DCS because the need to continue therapy for maintenance of benefit and the serious adverse effects associated with long-term systemic corticosteroid therapy. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedural therapies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lasers</strong> – Examples of laser interventions described as beneficial in case reports include laser hair reduction with a long-pulsed neodymium-doped yttrium aluminum garnet (Nd:YAG) [<a href="#rid63">63</a>] or pulsed diode [<a href="#rid64">64</a>] laser, laser resurfacing with a carbon dioxide (CO<sub>2</sub>) laser [<a href="#rid65">65</a>], and treatment with a 2940 nm multifractional erbium-doped yttrium aluminum garnet (Er:YAG) laser [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Photodynamic therapy</strong> – <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">Aminolevulinic acid</a> photodynamic therapy was associated with improvement in case reports and small case series [<a href="#rid67">67-70</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intracavitary foam sclerotherapy</strong> – Use of intracavitary foam sclerotherapy as a method of inducing fibrosis within fluid-filled subcutaneous cavities in DCS was associated with improvement in signs and symptoms of DCS in a case series of three patients. [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiation</strong> – Near-complete or complete remission after x-ray epilation has been documented in case reports and small case series [<a href="#rid35">35</a>]. However, use of x-ray epilation for DCS has fallen out of favor due to long-term safety concerns.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pressure dressings</strong> – Resolution of a fluctuant nodule refractory to medical therapy with use of a pressure dressing for four months is documented in a case report [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H192597804"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Because DCS is a chronic disorder with frequent relapses, long-term follow-up is essential. Some hair regrowth may occur once the disease is satisfactorily controlled in sites where sufficient damage to the hair follicles has not occurred. Patchy scarring alopecia can develop in longstanding cases [<a href="#rid22">22</a>].</p><p>Rare complications include squamous cell carcinoma in longstanding disease [<a href="#rid73">73</a>] and calvarial osteomyelitis [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H192597810"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disease of the scalp that can result in scarring and permanent hair loss. DCS most commonly affects adult males; however, other individuals can develop DCS. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Prognosis and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of DCS is unclear. The disease may result from a defect of follicular keratinization that leads to obstruction of hair follicles. DCS may occur in association with other follicular occlusive disorders. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with DCS typically develop multiple boggy, suppurative nodules on the vertex and posterior scalp with interconnecting sinus tracts  (<a class="graphic graphic_picture graphicRef91508 graphicRef75929 graphicRef103149 graphicRef103150 graphicRef103151" href="/z/d/graphic/91508.html" rel="external">picture 1A-E</a>). Purulent or bloody drainage is common. Hair loss is usually patchy. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A diagnosis of DCS usually can be made based upon the patient history and physical examination. A bacterial culture should be performed to rule out secondary infection. When the diagnosis is uncertain, a scalp biopsy can be helpful for confirming DCS. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Data on the treatment of DCS are limited, and the ideal approach to treatment is unclear. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment</strong> – For the initial treatment of DCS, we suggest a course of oral <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> rather than other treatments  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">For most patients with an inadequate response to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, we suggest a trial of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> prior to proceeding to other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Tetracyclines are generally well tolerated, and in our experience, some patients with inadequate responses to doxycycline have greater improvement with minocycline. However, proceeding directly to oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is a reasonable alternative, particularly for patients with severe DCS. (See <a class="local">'Preferred initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse after cessation of tetracyclines</strong> – The frequency of relapse influences our approach to DCS that responds to tetracyclines but relapses after cessation  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>). For patients with infrequent relapses (one or fewer relapses per year), we suggest a course of the previously effective antibiotic rather than other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with relapses treated with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, we suggest subsequent continuation of doxycycline at a subantimicrobial dose for maintenance therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">We manage patients with a higher frequency of relapse (&gt;1 relapse per year) or rapid relapse (eg, relapse within three months after treatment cessation) similarly to patients with disease refractory to tetracyclines.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease refractory to tetracyclines</strong> – For patients with DCS that cannot be adequately controlled with oral tetracyclines, we suggest oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> rather than other therapies  (<a class="graphic graphic_algorithm graphicRef143294" href="/z/d/graphic/143294.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment with a biologic tumor necrosis factor (TNF) inhibitor (<a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> or <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>) or combination therapy with <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is an alternative next-line therapy for patients who cannot receive oral isotretinoin. (See <a class="local">'Biologic TNF inhibitors'</a> above and <a class="local">'Clindamycin and rifampin'</a> above.)</p><p></p><p class="bulletIndent2">Surgical excision is an option for disease that cannot be satisfactorily managed with medical therapy. Surgical excision may lead to long-term remission but typically results in extensive scarring. (See <a class="local">'Surgical excision'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute treatment of painful, fluctuant nodules</strong> – Adjunctive intralesional corticosteroid injection and incision and drainage may be helpful for achieving rapid symptom relief. These interventions do not alter the course of the disease and should not be used as primary treatment.</p><p></p><p class="bulletIndent2">For patients with painful, nonfluctuant or minimally fluctuant nodules who require acute symptom relief, we suggest intralesional corticosteroid injection rather than incision and drainage (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients requiring relief from fluctuant, suppurative nodules, we suggest incision and drainage (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Painful or very fluctuant lesions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Scheinfeld N. Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa. Dermatol Online J 2014; 20:22692.</a></li><li><a class="nounderline abstract_t">Olsen EA, Bergfeld WF, Cotsarelis G, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol 2003; 48:103.</a></li><li><a class="nounderline abstract_t">Ramesh V. Dissecting cellulitis of the scalp in 2 girls. Dermatologica 1990; 180:48.</a></li><li><a class="nounderline abstract_t">El Sayed F, Ammoury A, Dhaybi R, et al. Perifolliculitis capitis abscedens et suffodiens: an unusual case triggered by trauma. J Eur Acad Dermatol Venereol 2006; 20:1143.</a></li><li><a class="nounderline abstract_t">Melo DF, Ramos PM, Machado CJ, et al. Dissecting cellulitis in women: a retrospective multicenter study with 17 patients. Int J Dermatol 2022; 61:e427.</a></li><li><a class="nounderline abstract_t">Arneja JS, Vashi CN, Gursel E, Lelli JL. Management of fulminant dissecting cellulitis of the scalp in the pediatric population: Case report and literature review. Can J Plast Surg 2007; 15:211.</a></li><li><a class="nounderline abstract_t">Lee CN, Chen W, Hsu CK, et al. Dissecting folliculitis (dissecting cellulitis) of the scalp: a 66-patient case series and proposal of classification. J Dtsch Dermatol Ges 2018; 16:1219.</a></li><li><a class="nounderline abstract_t">Vañó-Galván S, Saceda-Corralo D, Blume-Peytavi U, et al. Frequency of the Types of Alopecia at Twenty-Two Specialist Hair Clinics: A Multicenter Study. Skin Appendage Disord 2019; 5:309.</a></li><li><a class="nounderline abstract_t">Segurado-Miravalles G, Camacho-Martínez FM, Arias-Santiago S, et al. Epidemiology, clinical presentation and therapeutic approach in a multicentre series of dissecting cellulitis of the scalp. J Eur Acad Dermatol Venereol 2017; 31:e199.</a></li><li><a class="nounderline abstract_t">Badaoui A, Reygagne P, Cavelier-Balloy B, et al. Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature. Br J Dermatol 2016; 174:421.</a></li><li><a class="nounderline abstract_t">Koudoukpo C, Abdennader S, Cavelier-Balloy B, et al. [Dissecting cellulitis of the scalp: a retrospective study of 7 cases confirming the efficacy of oral isotretinoin]. Ann Dermatol Venereol 2014; 141:500.</a></li><li><a class="nounderline abstract_t">Gamissans M, Romaní J, López-Llunell C, et al. Dissecting cellulitis of the scalp: A review on clinical characteristics and management options in a series of 14 patients. Dermatol Ther 2022; 35:e15626.</a></li><li><a class="nounderline abstract_t">Yoon J, Choi JW. Primary cicatricial alopecia in a single-race Asian population: A 10-year nationwide population-based study in South Korea. J Dermatol 2018; 45:1306.</a></li><li><a class="nounderline abstract_t">Jiang T, Liu C. Dissecting cellulitis of the scalp with typical clinical features: A retrospective cross-sectional study in a Department of Dermatology, Beijing, China. J Dermatol 2022; 49:1173.</a></li><li><a class="nounderline abstract_t">Whiting DA. Cicatricial alopecia: clinico-pathological findings and treatment. Clin Dermatol 2001; 19:211.</a></li><li><a class="nounderline abstract_t">Madu P, Kundu RV. Follicular and scarring disorders in skin of color: presentation and management. Am J Clin Dermatol 2014; 15:307.</a></li><li><a class="nounderline abstract_t">McMichael AJ. Hair and scalp disorders in ethnic populations. Dermatol Clin 2003; 21:629.</a></li><li><a class="nounderline abstract_t">Tran AX, Lefante JJ, Murina A. Risk factors for dissecting cellulitis of the scalp: A case-control study. J Am Acad Dermatol 2022; 86:941.</a></li><li><a class="nounderline abstract_t">Najjar SN, Rezigh AB. Dissecting Cellulitis of the Scalp. N Engl J Med 2023; 388:1608.</a></li><li><a class="nounderline abstract_t">Williams CN, Cohen M, Ronan SG, Lewandowski CA. Dissecting cellulitis of the scalp. Plast Reconstr Surg 1986; 77:378.</a></li><li><a class="nounderline abstract_t">Brook I. Recovery of anaerobic bacteria from a case of dissecting cellulitis. Int J Dermatol 2006; 45:168.</a></li><li><a class="nounderline abstract_t">Mundi JP, Marmon S, Fischer M, et al. Dissecting cellulitis of the scalp. Dermatol Online J 2012; 18:8.</a></li><li><a class="nounderline abstract_t">Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol 2022; 86:1092.</a></li><li><a class="nounderline abstract_t">Prasad SC, Bygum A. Successful treatment with alitretinoin of dissecting cellulitis of the scalp in keratitis-ichthyosis-deafness syndrome. Acta Derm Venereol 2013; 93:473.</a></li><li><a class="nounderline abstract_t">Zagelbaum Ward NK, Jun JA, Vecerek N, et al. Dissecting cellulitis of the scalp associated with peripheral and axial spondyloarthritis: report of a case and review of the literature. Clin Rheumatol 2022; 41:2553.</a></li><li><a class="nounderline abstract_t">Maintz L, Betz RC, Allam JP, et al. Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. Eur J Dermatol 2005; 15:347.</a></li><li><a class="nounderline abstract_t">Thein M, Hogarth MB, Acland K. Seronegative arthritis associated with the follicular occlusion triad. Clin Exp Dermatol 2004; 29:550.</a></li><li><a class="nounderline abstract_t">Libow LF, Friar DA. Arthropathy associated with cystic acne, hidradenitis suppurativa, and perifolliculitis capitis abscedens et suffodiens: treatment with isotretinoin. Cutis 1999; 64:87.</a></li><li><a class="nounderline abstract_t">Ongchi DR, Fleming MG, Harris CA. Sternocostoclavicular hyperostosis: two cases with differing dermatologic syndromes. J Rheumatol 1990; 17:1415.</a></li><li><a class="nounderline abstract_t">Brănişteanu DE, Molodoi A, Ciobanu D, et al. The importance of histopathologic aspects in the diagnosis of dissecting cellulitis of the scalp. Rom J Morphol Embryol 2009; 50:719.</a></li><li><a class="nounderline abstract_t">Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part II. Trichoscopic and laboratory evaluations. J Am Acad Dermatol 2014; 71:431.e1.</a></li><li><a class="nounderline abstract_t">Stein LL, Adams EG, Holcomb KZ. Inflammatory tinea capitis mimicking dissecting cellulitis in a postpubertal male: a case report and review of the literature. Mycoses 2013; 56:596.</a></li><li><a class="nounderline abstract_t">Sperling LC. Inflammatory tinea capitis (kerion) mimicking dissecting cellulitis. Occurrence in two adolescents. Int J Dermatol 1991; 30:190.</a></li><li><a class="nounderline abstract_t">Shastry J, Ciliberto H, Davis DM. Tinea capitis mimicking dissecting cellulitis in three children. Pediatr Dermatol 2018; 35:e79.</a></li><li><a class="nounderline abstract_t">Thomas J, Aguh C. Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review. J Dermatolog Treat 2021; 32:144.</a></li><li><a class="nounderline abstract_t">Koca R, Altinyazar HC, Ozen OI, Tekin NS. Dissecting cellulitis in a white male: response to isotretinoin. Int J Dermatol 2002; 41:509.</a></li><li><a class="nounderline abstract_t">Georgala S, Korfitis C, Ioannidou D, et al. Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: case reports. Cutis 2008; 82:195.</a></li><li><a class="nounderline abstract_t">Khaled A, Zeglaoui F, Zoghlami A, et al. Dissecting cellulitis of the scalp: response to isotretinoin. J Eur Acad Dermatol Venereol 2007; 21:1430.</a></li><li><a class="nounderline abstract_t">Dhaoui MA, Mebazaa A, Doss N. [Dissecting cellulitis of the scalp: treatment by isotretinoine]. Ann Dermatol Venereol 2001; 128:688.</a></li><li><a class="nounderline abstract_t">Scerri L, Williams HC, Allen BR. Dissecting cellulitis of the scalp: response to isotretinoin. Br J Dermatol 1996; 134:1105.</a></li><li><a class="nounderline abstract_t">Taylor AE. Dissecting cellulitis of the scalp: response to isotretinoin. Lancet 1987; 2:225.</a></li><li><a class="nounderline abstract_t">Guo W, Zhu C, Stevens G, Silverstein D. Analyzing the Efficacy of Isotretinoin in Treating Dissecting Cellulitis: A Literature Review and Meta-Analysis. Drugs R D 2021; 21:29.</a></li><li><a class="nounderline abstract_t">Melo DF, Trüeb RM, Dutra H, et al. Low-dose isotretinoin as a therapeutic option for dissecting cellulitis. Dermatol Ther 2020; 33:e14273.</a></li><li><a class="nounderline abstract_t">Sanchez-Diaz M, Martinez-Lopez A, Salvador-Rodriguez L, et al. The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. Dermatol Ther 2021; 34:e14829.</a></li><li><a class="nounderline abstract_t">Mansouri Y, Martin-Clavijo A, Newsome P, Kaur MR. Dissecting cellulitis of the scalp treated with tumour necrosis factor-α inhibitors: experience with two agents. Br J Dermatol 2016; 174:916.</a></li><li><a class="nounderline abstract_t">Navarini AA, Trüeb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol 2010; 146:517.</a></li><li><a class="nounderline abstract_t">Sukhatme SV, Lenzy YM, Gottlieb AB. Refractory dissecting cellulitis of the scalp treated with adalimumab. J Drugs Dermatol 2008; 7:981.</a></li><li><a class="nounderline abstract_t">Frechet L, Puzenat E, Charollais R, et al. Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series. Eur J Dermatol 2021; 31:81.</a></li><li><a class="nounderline abstract_t">Brandt HR, Malheiros AP, Teixeira MG, Machado MC. Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab. Br J Dermatol 2008; 159:506.</a></li><li><a class="nounderline abstract_t">Martin-García RF, Rullán JM. Refractory dissecting Cellulitis of the Scalp Successfully controlled with Adalimumab. P R Health Sci J 2015; 34:102.</a></li><li><a class="nounderline abstract_t">Wollina U, Gemmeke A, Koch A. Dissecting Cellulitis of the Scalp Responding to Intravenous Tumor Necrosis Factor-alpha Antagonist. J Clin Aesthet Dermatol 2012; 5:36.</a></li><li><a class="nounderline abstract_t">Cuellar TA, Roh DS, Sampson CE. Dissecting Cellulitis of the Scalp: A Review and Case Studies of Surgical Reconstruction. Plast Reconstr Surg Glob Open 2020; 8:e3015.</a></li><li><a class="nounderline abstract_t">Bolz S, Jappe U, Hartschuh W. Successful treatment of perifolliculitis capitis abscedens et suffodiens with combined isotretinoin and dapsone. J Dtsch Dermatol Ges 2008; 6:44.</a></li><li><a class="nounderline abstract_t">Greenblatt DT, Sheth N, Teixeira F. Dissecting cellulitis of the scalp responding to oral quinolones. Clin Exp Dermatol 2008; 33:99.</a></li><li><a class="nounderline abstract_t">Onderdijk AJ, Boer J. Successful treatment of dissecting cellulitis with ciprofloxacin. Clin Exp Dermatol 2010; 35:440.</a></li><li><a class="nounderline abstract_t">Onderdijk AJ, Boer J. Successful treatment of dissecting cellulitis with ciprofloxacin. Clin Exp Dermatol 2009; 34:e507.</a></li><li><a class="nounderline abstract_t">Awad A, Sinclair R. Treatment of dissecting cellulitis of the scalp with Tildrakizumab. Australas J Dermatol 2022; 63:404.</a></li><li><a class="nounderline abstract_t">Babalola F, Chima M, Jobarteh R, Gottlieb A. Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab. J Drugs Dermatol 2022; 21:313.</a></li><li><a class="nounderline abstract_t">Nagshabandi KN, Alsalhi A, Alahmadi D, et al. Refractory dissecting cellulitis of the scalp treated with risankizumab. JAAD Case Rep 2023; 42:P87.</a></li><li><a class="nounderline abstract_t">De Bedout V, Harper H, Miteva M, Lev-Tov H. Treatment Dissecting Cellulitis of the Scalp With Secukinumab. J Drugs Dermatol 2021; 20:776.</a></li><li><a class="nounderline abstract_t">Berne B, Venge P, Ohman S. Perifolliculitis capitis abscedens et suffodiens (Hoffman). Complete healing associated with oral zinc therapy. Arch Dermatol 1985; 121:1028.</a></li><li><a class="nounderline abstract_t">Kobayashi H, Aiba S, Tagami H. Successful treatment of dissecting cellulitis and acne conglobata with oral zinc. Br J Dermatol 1999; 141:1137.</a></li><li><a class="nounderline abstract_t">Krasner BD, Hamzavi FH, Murakawa GJ, Hamzavi IH. Dissecting cellulitis treated with the long-pulsed Nd:YAG laser. Dermatol Surg 2006; 32:1039.</a></li><li><a class="nounderline abstract_t">Boyd AS, Binhlam JQ. Use of an 800-nm pulsed-diode laser in the treatment of recalcitrant dissecting cellulitis of the scalp. Arch Dermatol 2002; 138:1291.</a></li><li><a class="nounderline abstract_t">Glass LF, Berman B, Laub D. Treatment of perifolliculitis capitis abscedens et suffodiens with the carbon dioxide laser. J Dermatol Surg Oncol 1989; 15:673.</a></li><li><a class="nounderline abstract_t">Xu M, Yan J. 2940-nm multifractional erbium:yttrium-aluminum-garnet laser for the treatment of dissecting cellulitis of the scalp: Case reports and literature review. J Dermatol 2022; 49:e230.</a></li><li><a class="nounderline abstract_t">Zhan Y, Chen X, Zhou Y, et al. Dissecting cellulitis of the scalp successfully treated with ALA-PDT: Case report. Photodiagnosis Photodyn Ther 2018; 24:182.</a></li><li><a class="nounderline abstract_t">Liu Y, Ma Y, Xiang LH. Successful treatment of recalcitrant dissecting cellulitis of the scalp with ALA-PDT: case report and literature review. Photodiagnosis Photodyn Ther 2013; 10:410.</a></li><li><a class="nounderline abstract_t">Feng Y, Zhang Y, Guo H, et al. Treatment of dissecting cellulitis of the scalp with 10% ALA-PDT. Lasers Surg Med 2019; 51:332.</a></li><li><a class="nounderline abstract_t">Liu H, Ding A, Aloke G, et al. Surgical interventions combined with photodynamic therapy in the treatment of Perifolliculitis Capitis Abscendens et Suffodiens: Report of 5 cases. Photodiagnosis Photodyn Ther 2020; 30:101660.</a></li><li><a class="nounderline abstract_t">Aboul-Fettouh N, Silapunt S, Mays S, Nguyen T. Intracavitary Foam Sclerotherapy in Dissecting Cellulitis of the Scalp. Dermatol Surg 2021; 47:1317.</a></li><li><a class="nounderline abstract_t">Asemota E, Chang YC, Goldberg LJ. Innovative Management of Recalcitrant Dissecting Cellulitis With Compression Therapy. JAMA Dermatol 2016; 152:1280.</a></li><li><a class="nounderline abstract_t">Curry SS, Gaither DH, King LE Jr. Squamous cell carcinoma arising in dissecting perifolliculitis of the scalp. A case report and review of secondary squamous cell carcinomas. J Am Acad Dermatol 1981; 4:673.</a></li><li><a class="nounderline abstract_t">Ramasastry SS, Granick MS, Boyd JB, Futrell JW. Severe perifolliculitis capitis with osteomyelitis. Ann Plast Surg 1987; 18:241.</a></li></ol></div><div id="topicVersionRevision">Topic 15682 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24852785" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppurativa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522378" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2106459" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dissecting cellulitis of the scalp in 2 girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987280" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perifolliculitis capitis abscedens et suffodiens: an unusual case triggered by trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35569091" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dissecting cellulitis in women: a retrospective multicenter study with 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19554179" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of fulminant dissecting cellulitis of the scalp in the pediatric population: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168900" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dissecting folliculitis (dissecting cellulitis) of the scalp: a 66-patient case series and proposal of classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31559256" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Frequency of the Types of Alopecia at Twenty-Two Specialist Hair Clinics: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27558283" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology, clinical presentation and therapeutic approach in a multicentre series of dissecting cellulitis of the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26134994" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25209812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : [Dissecting cellulitis of the scalp: a retrospective study of 7 cases confirming the efficacy of oral isotretinoin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35674720" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dissecting cellulitis of the scalp: A review on clinical characteristics and management options in a series of 14 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188582" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Primary cicatricial alopecia in a single-race Asian population: A 10-year nationwide population-based study in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35996875" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dissecting cellulitis of the scalp with typical clinical features: A retrospective cross-sectional study in a Department of Dermatology, Beijing, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397600" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cicatricial alopecia: clinico-pathological findings and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24820821" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Follicular and scarring disorders in skin of color: presentation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717404" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hair and scalp disorders in ethnic populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33785386" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk factors for dissecting cellulitis of the scalp: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37092782" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dissecting Cellulitis of the Scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3513219" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dissecting cellulitis of the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445513" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recovery of anaerobic bacteria from a case of dissecting cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23286798" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dissecting cellulitis of the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33493574" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150172" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Successful treatment with alitretinoin of dissecting cellulitis of the scalp in keratitis-ichthyosis-deafness syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460009" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dissecting cellulitis of the scalp associated with peripheral and axial spondyloarthritis: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172043" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347350" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Seronegative arthritis associated with the follicular occlusion triad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10467498" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Arthropathy associated with cystic acne, hidradenitis suppurativa, and perifolliculitis capitis abscedens et suffodiens: treatment with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2254905" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sternocostoclavicular hyperostosis: two cases with differing dermatologic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19942972" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The importance of histopathologic aspects in the diagnosis of dissecting cellulitis of the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128119" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evaluation and diagnosis of the hair loss patient: part II. Trichoscopic and laboratory evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582018" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inflammatory tinea capitis mimicking dissecting cellulitis in a postpubertal male: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2037403" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inflammatory tinea capitis (kerion) mimicking dissecting cellulitis. Occurrence in two adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29265536" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tinea capitis mimicking dissecting cellulitis in three children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31348693" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12207770" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Dissecting cellulitis in a white male: response to isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18856159" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958864" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dissecting cellulitis of the scalp: response to isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427813" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : [Dissecting cellulitis of the scalp: treatment by isotretinoine].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8763434" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dissecting cellulitis of the scalp: response to isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2885687" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dissecting cellulitis of the scalp: response to isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33387328" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Analyzing the Efficacy of Isotretinoin in Treating Dissecting Cellulitis: A Literature Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32890448" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Low-dose isotretinoin as a therapeutic option for dissecting cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527618" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527324" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dissecting cellulitis of the scalp treated with tumour necrosis factor-αinhibitors: experience with two agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231491" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19112766" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Refractory dissecting cellulitis of the scalp treated with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33648906" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547307" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061062" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Refractory dissecting Cellulitis of the Scalp Successfully controlled with Adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22708007" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dissecting Cellulitis of the Scalp Responding to Intravenous Tumor Necrosis Factor-alpha Antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32983774" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dissecting Cellulitis of the Scalp: A Review and Case Studies of Surgical Reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908178" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful treatment of perifolliculitis capitis abscedens et suffodiens with combined isotretinoin and dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18039341" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dissecting cellulitis of the scalp responding to oral quinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19758386" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Successful treatment of dissecting cellulitis with ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19747334" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Successful treatment of dissecting cellulitis with ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35510345" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of dissecting cellulitis of the scalp with Tildrakizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35254754" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Refractory dissecting cellulitis of the scalp treated with risankizumab</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34231997" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment Dissecting Cellulitis of the Scalp With Secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026339" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Perifolliculitis capitis abscedens et suffodiens (Hoffman). Complete healing associated with oral zinc therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10722268" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful treatment of dissecting cellulitis and acne conglobata with oral zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16918566" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Dissecting cellulitis treated with the long-pulsed Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12374532" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Use of an 800-nm pulsed-diode laser in the treatment of recalcitrant dissecting cellulitis of the scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2723230" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of perifolliculitis capitis abscedens et suffodiens with the carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35318708" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : 2940-nm multifractional erbium:yttrium-aluminum-garnet laser for the treatment of dissecting cellulitis of the scalp: Case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30290230" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Dissecting cellulitis of the scalp successfully treated with ALA-PDT: Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284093" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful treatment of recalcitrant dissecting cellulitis of the scalp with ALA-PDT: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30136732" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of dissecting cellulitis of the scalp with 10% ALA-PDT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109620" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Surgical interventions combined with photodynamic therapy in the treatment of Perifolliculitis Capitis Abscendens et Suffodiens: Report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448768" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intracavitary Foam Sclerotherapy in Dissecting Cellulitis of the Scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27533482" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Innovative Management of Recalcitrant Dissecting Cellulitis With Compression Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7240474" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Squamous cell carcinoma arising in dissecting perifolliculitis of the scalp. A case report and review of secondary squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3592511" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe perifolliculitis capitis with osteomyelitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
